In the presence of phosphine catalyst and pinacolborane, ynones undergo 1,2-reduction while ynoates undergotrans-hydroboration. Mechanistic insights into the two competing pathways lay grounds for control of selectivity in these processes.
Gold-catalyzed Fluorination of Alkynyl Esters and Ketones: Efficient Access to Fluorinated 1,3-Dicarbonyl Compounds
作者:Xiaojun Zeng、Zhichao Lu、Shiwen Liu、Gerald B. Hammond、Bo Xu
DOI:10.1002/adsc.201701179
日期:2017.11.23
We developed an efficient synthesis of 2-fluoro-1,3-dicarbonyl compounds using readily available alkynyl ketones or esters as starting material. The key step is the insertion of hydrogen fluoride (HF) to the gold carbene intermediate generated from cationic gold catalyzed addition of N-oxides to alkynyl ketones or esters. This method gives excellent chemical yields and regioselectivity with good functional
Ni<sup>I</sup>Catalyzes the Regioselective Cross-Coupling of Alkylzinc Halides and Propargyl Bromides to Allenes
作者:Rita Soler-Yanes、Iván Arribas-Álvarez、Manuel Guisán-Ceinos、Elena Buñuel、Diego J. Cárdenas
DOI:10.1002/chem.201603758
日期:2017.1.31
We describe the unprecedented formation of allenes by Ni‐catalyzed cross‐coupling of propargyl bromides with alkylzinc halides. The reaction regioselectivity is complementary to the previously reported formation of propargyl‐coupled compounds. Experiments support the formation of NiI complexes as the active species and the participation of radical intermediates. Kinetic studies showed that the reaction
The charge‐accelerated aza‐Claisen rearrangement of ammonium salts serves as a key step in the construction of complex nitrogen‐containing molecules. However, much less attention has been paid to the aromatic aza‐Claisen rearrangement than to the aliphatic one. Herein, we report an unprecedented aromatic aza‐Claisen rearrangement of arylpropargylammonium salts, generated in situ from arynes and tertiary
Pyridine and pyrimidine derivatives as mGIuR2 antagonists
申请人:McArthur Silvia Gatti
公开号:US20070232583A1
公开(公告)日:2007-10-04
The present invention relates to compounds of formula (I), a process for the manufacture thereof, pharmaceutical compositions containing them, and their use for treating CNS disorders:
wherein A, B, X, Y, R
1
, R
2
, R
3
and R
4
are as defined in the description and claims.